Myriad Genetics, Inc. and Personalis, Inc. announced a non-exclusive collaboration through which Myriad will market the Personalis® ImmunoID NeXT ultra-comprehensive biomarker discovery platform to its pharmaceutical partners who use the MyRisk® Hereditary Cancer Test, BRACAnalysis CDx® and/or MyChoice® CDx cancer tests. Personalis? ImmunoID NeXT platform is the most discriminating platform to power drug development biomarker efforts and has been utilized by the top 20 global bio-pharma companies.

It provides high-quality exome/transcriptome assays for cancer FFPE samples.